Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Basic & Clinical Pharmacology & Toxicology|August 4, 2023
Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitorsFeng Deng, Johanna Sistonen, Mikko Neuvonen, et al.Journal of Analytical Toxicology|June 25, 2003
Screening for basic drugs in 2-mL urine samples by dual-plate overpressured layer chromatography and comparison with gas chromatography-mass spectrometryAnna Pelander, Ilkka Ojanperä, Johanna Sistonen, et al.The American Journal of Forensic Medicine and Pathology|August 28, 2007
A fatal doxepin poisoning associated with a defective CYP2D6 genotypeAnna Koski, Ilkka Ojanperä, Johanna Sistonen, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|September 1, 2012
A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapyJohanna Sistonen, Chingying Smith, Yung-Kang Fu, et al.Forensic Science International|July 19, 2005
CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsiesAnna Koski, Johanna Sistonen, Ilkka Ojanperä, et al.Therapeutic Drug Monitoring|August 2, 2007
Quantification of drugs in plasma without primary reference standards by liquid chromatography-chemiluminescence nitrogen detection: application to tramadol metabolite ratiosSuvi Ojanperä, Ilpo Rasanen, Johanna Sistonen, et al.Pharmacogenetics and Genomics|February 16, 2007
CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structureJohanna Sistonen, Antti Sajantila, Oscar Lao, et al.Clinical Chemistry and Laboratory Medicine|February 16, 2013
Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patientsBarbara Büchel, Johanna Sistonen, Markus Joerger, et al.Pharmacogenetics and Genomics|January 20, 2009
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scalesJohanna Sistonen, Silvia Fuselli, Jukka U Palo, et al.Journal of Cardiovascular Pharmacology|March 10, 2011
Pharmacogenomics of cardiovascular drugs and adverse effects in pediatricsHenk Visscher, Ursula Amstutz, Johanna Sistonen, et al.Pageof 4